Novo Nordisk’s diabetes medicine Rybelsus, an oral form of the GLP-1 drug semaglutide, provides similar cardiovascular ...

In the SOUL trial, Rybelsus produced a 14% risk reduction of major adverse cardiovascular events in patients with type 2 ...

The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart ...

Novo Nordisk (NVO) stock dropped on Monday despite the drugmaker reporting positive results for its GLP-1 medicine, Rybelsus.

Novo Nordisk already has broad FDA approvals in hand for its injected semaglutide products Ozempic and Wegovy to reduce the ...

Novo Nordisk’s diabetes pill Rybelsus, an oral semaglutide, reduced the risk of major heart-related events by 14% in adults with Type 2 diabetes and cardiovascular disease or chronic kidney disease, ...

Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...

According to BMO Capital Markets, Rybelsus’ outcomes in SOUL were “inconsistent,” failing to significantly lower ...

Bagsværd, Denmark Tuesday, April 1, 2025, 18:00 Hrs [IST] ...

BAGSVAERD, Denmark I March 29, 2025 I Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® ...

Rybelsus ® reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and/or chronic kidney disease in the SOUL cardiovascular outcomes trial 1.

Novo Nordisk on Saturday said its diabetes pill Rybelsus showed cardiovascular benefits in a late-stage trial, paving the way for it to become a new treatment option for people living with ...